JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of a new cold field emission cryo-electron microscope (cryo-EM), the CRYO ARM™ 300 II (JEM-3300), to be released in January 2021. This new cryo-EM has been developed based on the concept of "Quick and easy to operate and get high-contrast and high-resolution images".
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210121005316/en/
Cold Field Emission Cryo-Electron Microscope CRYO ARM(TM) 300 II (JEM-3300) (Photo: Business Wire)
Development Background
Recent dramatic improvement of resolution in single particle analysis (SPA) using cryo-EM has led to SPA as an essential method for structural analysis of proteins. To address this market, JEOL released the CRYO ARM™ 300 in 2017. Equipped with a cold field emission gun (Cold FEG) for enhanced resolution and a cryo-stage for loading multiple samples, the CRYO ARM™ 300 has continued to achieve best-in-class resolution for SPA.
However, the previous workflow of SPA using cryo-EM needs multiple electron microscopes because the workflows for sample screening and for image data acquisition are independent of one another. This problem gives rise to large operating costs for cryo-EM users. Since multiple microscopes must be used, it is inconvenient to transfer cryo-samples between the cryo-EMs. Therefore, users have been requesting one cryo-EM enabling the complete workflow from sample screening to image data acquisition. Furthermore, in order for various users to use the cryo-EM, an improvement of usability has been required, allowing anyone from novice users to professional users to smoothly operate the microscope.
To meet these requests, JEOL has developed a new cryo-EM, the CRYO ARM™ 300 II. This microscope achieves a great improvement in throughput for high-quality data acquisition with quick and easy operation compared with the previous CRYO ARM™ 300.
Main Features
1. High-speed imaging achieved by optimal electron beam control
2. Improved hardware stability for high-quality image acquisition
3. Higher operability through system improvement
Annual unit sales target
10 units/year
Cold Field Emission Cryo-Electron Microscope CRYO ARM™ 300 II (JEM-3300)
https://www.jeol.co.jp/en/products/detail/JEM-3300.html
JEOL Ltd.
3-1-2, Musashino, Akishima, Tokyo, 196-8558, Japan
Izumi Oi, President & COO
(Stock code: 6951, Tokyo Stock Exchange First Section)
www.jeol.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210121005316/en/
JEOL Ltd.
Science and Measurement Instruments Sales Division
Hideya UENO
+81-3-6262-3567
https://www.jeol.co.jp/en/support/support_system/contact_products.html
More News from JEOL Ltd. |
JEOL: Release of the New Gas Chromatograph – Time-of-flight Mass Spectrometer JMS-T2000GC AccuTOF(TM) GC-Alpha – the Ultimate GC-MS With Superior Performance and Ease of Operation17/02/2021 10:00AM JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of JMS-T2000GC "AccuTOF(TM) GC-Alpha", the latest model of the successful AccuTOF(TM) GC series gas chromatograph – ... US Department of Homeland Security, Customs and Border Protection, Selects JEOL Mass Spectrometers for Five Labs10/06/2020 12:22PM JEOL USA, INC., a wholly owned subsidiary of JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi), has been awarded a major contract by the US Department of Homeland Security Customs and Border Protection (DHS – ... JEOL: Release of the New Scanning Electron Microscope JSM-IT700HR04/08/2020 1:00PM JEOL Ltd. (TOKYO:6951) (President & COO Izumi Oi) announces the release of a new scanning electron microscope (SEM), the JSM-IT700HR for unprecedentedly high throughput in August 2020. This press release ... |
Similar News |
Neelkanth Jewellers Launches Forevermark at HSR Layout - Bengaluru03/03/2021 6:24PM Strengthening their association with Forevermark, Neelkanth Jewelers launched the diamond brand from the De Beers Group, at their store at HSR layout, Bengaluru today. Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome03/03/2021 6:00PM − Ovid eligible to receive up to $856M in payments, including a $196M upfront payment, regulatory and commercial milestone payments and tiered double-digit royalties on product sales − Potential ... |